Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1992 Feb;65(2):271–274. doi: 10.1038/bjc.1992.54

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases.

C Wright 1, J Cairns 1, B J Cantwell 1, A R Cattan 1, A G Hall 1, A L Harris 1, C H Horne 1
PMCID: PMC1977713  PMID: 1346748

Abstract

Sixty-eight patients with advanced breast cancer were treated with mitoxantrone and clinical responses assessed. Expression of c-erbB-2 protein and cytosolic glutathione S-transferase (GST) isoenzymes pi, alpha and mu by the primary tumours of these patients was determined immunohistochemically, and correlated with treatment response. Tumours overexpressing c-erbB-2 (n = 16, 23%) showed a lower response rate (50% vs 58%) and shorter duration of response to treatment, compared with c-erbB-2 negative tumours. These associations were not statistically significant but survival following start of treatment was significantly shorter in the c-erbB-2 positive group. For each GST isoenzyme, the response rate and duration of response of the group showing enzyme expression did not differ significantly from those with negatively staining tumours. These data do not support a role for expression of GSTs alone in resistance to mitoxantrone monotherapy in advanced breast cancer. The poorer post treatment survival of patients with c-erbB-2 positive tumours suggests they could be selected for more intensive treatment regimens.

Full text

PDF
271

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 1991 Jan;6(1):137–143. [PubMed] [Google Scholar]
  2. Boyer T. D. The glutathione S-transferases: an update. Hepatology. 1989 Mar;9(3):486–496. doi: 10.1002/hep.1840090324. [DOI] [PubMed] [Google Scholar]
  3. Fisher B., Fisher E. R., Redmond C. Ten-year results from the National Surgical Adjuvant Breast and Bowel Project (NSABP) clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 1986 Jun;4(6):929–941. doi: 10.1200/JCO.1986.4.6.929. [DOI] [PubMed] [Google Scholar]
  4. Hall A., Foster S., Proctor S. J., Cattan A. R. Purification and characterization of a pi class glutathione S-transferase from human leukaemic cells. Br J Haematol. 1990 Dec;76(4):494–500. doi: 10.1111/j.1365-2141.1990.tb07906.x. [DOI] [PubMed] [Google Scholar]
  5. Harris A. L., Cantwell B. M., Carmichael J., Wilson R., Farndon J., Dawes P., Ghani S., Evans R. G. Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer. Lancet. 1990 Jan 27;335(8683):186–190. doi: 10.1016/0140-6736(90)90277-c. [DOI] [PubMed] [Google Scholar]
  6. Henderson I. C., Allegra J. C., Woodcock T., Wolff S., Bryan S., Cartwright K., Dukart G., Henry D. Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol. 1989 May;7(5):560–571. doi: 10.1200/JCO.1989.7.5.560. [DOI] [PubMed] [Google Scholar]
  7. Howie A. F., Miller W. R., Hawkins R. A., Hutchinson A. R., Beckett G. J. Expression of glutathione S-transferase B1, B2, Mu and Pi in breast cancers and their relationship to oestrogen receptor status. Br J Cancer. 1989 Dec;60(6):834–837. doi: 10.1038/bjc.1989.375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Keith W. N., Stallard S., Brown R. Expression of mdr1 and gst-pi in human breast tumours: comparison to in vitro chemosensitivity. Br J Cancer. 1990 May;61(5):712–716. doi: 10.1038/bjc.1990.160. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lewis A. D., Forrester L. M., Hayes J. D., Wareing C. J., Carmichael J., Harris A. L., Mooghen M., Wolf C. R. Glutathione S-transferase isoenzymes in human tumours and tumour derived cell lines. Br J Cancer. 1989 Sep;60(3):327–331. doi: 10.1038/bjc.1989.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lewis S., Locker A., Todd J. H., Bell J. A., Nicholson R., Elston C. W., Blamey R. W., Ellis I. O. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990 May;43(5):385–389. doi: 10.1136/jcp.43.5.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Litherland S., Jackson I. M. Antioestrogens in the management of hormone-dependent cancer. Cancer Treat Rev. 1988 Sep;15(3):183–194. doi: 10.1016/0305-7372(88)90002-3. [DOI] [PubMed] [Google Scholar]
  12. Mannervik B., Alin P., Guthenberg C., Jensson H., Tahir M. K., Warholm M., Jörnvall H. Identification of three classes of cytosolic glutathione transferase common to several mammalian species: correlation between structural data and enzymatic properties. Proc Natl Acad Sci U S A. 1985 Nov;82(21):7202–7206. doi: 10.1073/pnas.82.21.7202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Mittra I. Has adjuvant treatment of breast cancer had an unfair trial? BMJ. 1990 Dec 8;301(6764):1317–1319. doi: 10.1136/bmj.301.6764.1317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Morgenstern R., DePierre J. W., Jörnvall H. Microsomal glutathione transferase. Primary structure. J Biol Chem. 1985 Nov 15;260(26):13976–13983. [PubMed] [Google Scholar]
  15. Moscow J. A., Townsend A. J., Goldsmith M. E., Whang-Peng J., Vickers P. J., Poisson R., Legault-Poisson S., Myers C. E., Cowan K. H. Isolation of the human anionic glutathione S-transferase cDNA and the relation of its gene expression to estrogen-receptor content in primary breast cancer. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6518–6522. doi: 10.1073/pnas.85.17.6518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nicholson S., Sainsbury J. R., Halcrow P., Chambers P., Farndon J. R., Harris A. L. Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet. 1989 Jan 28;1(8631):182–185. doi: 10.1016/s0140-6736(89)91202-6. [DOI] [PubMed] [Google Scholar]
  17. Ong G., Gullick W., Sikora K. Oncoprotein stability after tumour resection. Br J Cancer. 1990 Apr;61(4):538–542. doi: 10.1038/bjc.1990.121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Perren T. J. c-erbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer. 1991 Mar;63(3):328–332. doi: 10.1038/bjc.1991.78. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelénat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst. 1989 Sep 20;81(18):1383–1387. doi: 10.1093/jnci/81.18.1383. [DOI] [PubMed] [Google Scholar]
  20. Sainsbury J. R., Farndon J. R., Needham G. K., Malcolm A. J., Harris A. L. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987 Jun 20;1(8547):1398–1402. doi: 10.1016/s0140-6736(87)90593-9. [DOI] [PubMed] [Google Scholar]
  21. Schneider J., Bak M., Efferth T., Kaufmann M., Mattern J., Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer. 1989 Dec;60(6):815–818. doi: 10.1038/bjc.1989.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Shenkenberg T. D., Von Hoff D. D. Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med. 1986 Jul;105(1):67–81. doi: 10.7326/0003-4819-105-1-67. [DOI] [PubMed] [Google Scholar]
  23. Verrelle P., Meissonnier F., Fonck Y., Feillel V., Dionet C., Kwiatkowski F., Plagne R., Chassagne J. Clinical relevance of immunohistochemical detection of multidrug resistance P-glycoprotein in breast carcinoma. J Natl Cancer Inst. 1991 Jan 16;83(2):111–116. doi: 10.1093/jnci/83.2.111. [DOI] [PubMed] [Google Scholar]
  24. Waxman D. J. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review. Cancer Res. 1990 Oct 15;50(20):6449–6454. [PubMed] [Google Scholar]
  25. Wishart G. C., Plumb J. A., Going J. J., McNicol A. M., McArdle C. S., Tsuruo T., Kaye S. B. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer. 1990 Nov;62(5):758–761. doi: 10.1038/bjc.1990.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Wolf C. R., Macpherson J. S., Smyth J. F. Evidence for the metabolism of mitozantrone by microsomal glutathione transferases and 3-methylcholanthrene-inducible glucuronosyl transferases. Biochem Pharmacol. 1986 May 1;35(9):1577–1581. doi: 10.1016/0006-2952(86)90127-9. [DOI] [PubMed] [Google Scholar]
  27. Wright C., Angus B., Nicholson S., Sainsbury J. R., Cairns J., Gullick W. J., Kelly P., Harris A. L., Horne C. H. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989 Apr 15;49(8):2087–2090. [PubMed] [Google Scholar]
  28. di Ilio C., Sacchetta P., del Boccio G., la Rovere G., Federici G. Glutathione peroxidase, glutathione S-transferase and glutathione reductase activities in normal and neoplastic human breast tissue. Cancer Lett. 1985 Oct;29(1):37–42. doi: 10.1016/0304-3835(85)90120-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES